Ziconotide is a synthetic peptide analgesic, and one of the small number of peptides in this reference that holds a UK marketing authorisation. It is also the least conventional of them: it is delivered directly into the cerebrospinal fluid through an implanted intrathecal pump, and it is never supplied to patients for self-administration. That combination — a licensed peptide whose route of administration removes it entirely from the consumer market — is what makes it worth a standalone entry.
What ziconotide is
Ziconotide is a 25-amino-acid synthetic peptide. It is the synthetic equivalent of omega-conotoxin MVIIA, a component of the venom of the piscivorous marine cone snail Conus magus. The conotoxin evolved to block the calcium channels that carry pain signals; ziconotide is that pharmacophore, produced to pharmaceutical standards rather than as a venom component.
Mechanism
Ziconotide is a selective blocker of the N-type voltage-gated calcium channel (Cav2.2). Those channels sit on the presynaptic terminals of primary nociceptive afferents in the dorsal horn of the spinal cord. Blocking them reduces calcium-dependent release of pronociceptive neurotransmitters, dampening transmission of the pain signal upstream. It is a non-opioid mechanism: ziconotide does not act at opioid receptors, and it does not prevent or relieve opioid withdrawal.
UK and EU regulatory position
The European Commission granted a marketing authorisation valid throughout the EU for Prialt on 21 February 2005. The licence was held originally by Elan Pharmaceuticals and transferred to Eisai Ltd in September 2006. Ziconotide had been designated an orphan medicine by the European Medicines Agency in 2001, and the UK launch followed in July 2006. The licensed indication is the treatment of severe, chronic pain in patients who require intrathecal analgesia.
In the UK it is a prescription-only medicine. Licensed supply sits under the Medicines Act 1968 and the Human Medicines Regulations 2012, and the product is a hospital-specialist medicine delivered by continuous intrathecal infusion under clinician supervision.
Access within the NHS has not been uniform. In June 2008 the All Wales Medicines Strategy Group did not recommend ziconotide for this indication, finding that the case for cost-effectiveness had not been proven. That is a commissioning decision rather than a safety one, and it is worth stating plainly: a UK licence and routine NHS funding are two different things.
What the trial evidence shows
The pivotal evidence remains the two randomised, placebo-controlled trials of intrathecal ziconotide. The first, in patients with cancer- or AIDS-related refractory pain, was published in JAMA in 2004. The second, in adults with severe chronic nonmalignant pain, was published in 2006. Both reported reductions in pain intensity against placebo, and both reported a substantial burden of central nervous system adverse effects — dizziness, confusion and abnormal coordination among them — requiring slow, clinician-supervised titration and monitoring.
That profile is the honest headline. Ziconotide is a licensed medicine with a real but narrow place in intrathecal analgesia for patients who have not responded to, or cannot tolerate, other options. It is not a general-purpose analgesic, and the evidence does not support describing it as one. On this reference's four-tier scale the licensed indication rests on randomised trial data; the wider claims made for conopeptides in grey-market material do not.
Where it sits relative to the grey market
Ziconotide is occasionally listed by research-chemical suppliers. That framing should be read carefully. As a licensed medicine it exists only as a sterile solution for intrathecal infusion, supplied through a controlled pharmaceutical chain. Because its administration route is an implanted intrathecal catheter and pump, the compound has no plausible consumer or self-administration use. Material sold as "ziconotide" outside that chain is not the licensed product and carries none of its quality assurances.
As with every compound in this reference, ziconotide is described for research and reference purposes only. Nothing here is consumption, dosing or self-administration guidance, and research-use-only framing applies throughout.
Adverse-event reporting in the UK
Suspected adverse reactions to ziconotide, as to any UK medicine, should be reported through the MHRA Yellow Card scheme. Because ziconotide is used in a small, closely monitored hospital population, its Yellow Card record is correspondingly thin — a real limitation on what post-marketing data can say about rare effects.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.